Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04031456
Other study ID # PRP- POI
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date July 30, 2019
Est. completion date July 30, 2026

Study information

Verified date February 2023
Source Genesis Athens Clinic
Contact Mara Simopoulou, PhD
Phone +306979234100
Email marasimopoulou@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.


Description:

This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to patients presenting with POI. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in POI patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 30, 2026
Est. primary completion date January 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years to 39 Years
Eligibility Inclusion Criteria: - Age < 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels >25 IU/L recorded on two occasions >4 weeks apart - Normal Karyotype: 46, XX - Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. - Willing to comply with study requirements Exclusion Criteria: - Any pathological disorder related to reproductive system anatomy - AMH > 8 pmol/L - Endometriosis - Adenomyosis - Fibroids and adhesions - Infections in reproductive system - Current or previous diagnosis of cancer in reproductive system - History of familiar cancer in reproductive system - Severe male factor infertility - Prior referral for PGT - Ovarian inaccessibility - Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) - BMI>30 kg/m2 or BMI<18.5 kg/m2 - Systematic autoimmune disorders

Study Design


Intervention

Biological:
Autologous Platelet Rich Plasma
Autologous PRP intra ovarian infusion
Placebo-Platelet Free Plasma
Autologous PFP intra ovarian infusion

Locations

Country Name City State
Greece Genesis AC Athens

Sponsors (2)

Lead Sponsor Collaborator
Genesis Athens Clinic National and Kapodistrian University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Restoration of menstrual cycle Regular menstrual cycle Three months
Primary Serum FSH levels Serum FSH levels evaluated monthly for three consecutive months Follow-up period of three months entailing monthly evaluation
Secondary Serum AMH levels Serum ??? levels evaluated monthly for three consecutive months Follow-up period of three months entailing monthly evaluation
Secondary Serum LH levels Serum LH levels evaluated monthly for three consecutive months Follow-up period of three months entailing monthly evaluation
Secondary Serum Estradiol levels Serum estradiol levels evaluated monthly for three consecutive months Follow-up period of three months entailing monthly evaluation
Secondary Serum Progesteron levels Serum progesterone levels evaluated monthly for three consecutive months Follow-up period of three months entailing monthly evaluation
Secondary Antral Follicle Count (AFC) AFC evaluated monthly, on day 2 of the menstrual cycle, for three consecutive months Follow-up period of three months entailing monthly evaluation
See also
  Status Clinical Trial Phase
Unknown status NCT01853501 - Effects of ADSC Therapy in Women With POF Phase 4
Completed NCT00417066 - Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Phase 4
Active, not recruiting NCT04675970 - Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
Recruiting NCT03480412 - Second Step Protocol in Poor Ovarian Responder (POR)
Completed NCT02644447 - Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF Phase 1/Phase 2
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06117982 - The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency Phase 2
Suspended NCT03816852 - The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency Phase 2
Not yet recruiting NCT04390308 - Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
Completed NCT02783937 - Filgrastim for Premature Ovarian Insufficiency Phase 4
Completed NCT00295087 - X-Chromosome Inactivation Status and Premature Ovarian Failure N/A
Completed NCT00429494 - GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Phase 2
Not yet recruiting NCT05522634 - A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency Early Phase 1
Recruiting NCT05838157 - The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Withdrawn NCT01129947 - The Use of DHEA in Women With Premature Ovarian Failure Phase 0
Completed NCT00001275 - Ovarian Follicle Function in Patients With Primary Ovarian Failure N/A
Not yet recruiting NCT04306185 - Ovarian Fragmentation Study (Crespo Medical Team) N/A
Recruiting NCT02062931 - Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Phase 1/Phase 2
Completed NCT02151890 - Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure Phase 1/Phase 2